Colposcopy News and Research

RSS

Trained navigators can help patients overcome inequities in healthcare system

Traversing the healthcare system can be daunting for almost anyone. Add in the many obstacles that low-income uninsured populations face, and it becomes tremendously more difficult. But a new Northwestern Medicine study shows that guidance from trained navigators can help patients overcome healthcare inequities.

26 Feb 2015

NICE publishes Medtech Innovation Briefing on ZedScan

The NICE MIB has been developed on ZedScan as an adjunct to colposcopy in women with suspected cervical intra-epithelial neoplasia.

From Zilico 23 Feb 2015

Cervical treatment procedures do not affect fertility, shows study

Common surgical procedures used to diagnose and treat precancerous cervical lesions do not decrease women's chances of becoming pregnant, according to a study that followed nearly 100,000 women for up to 12 years.

12 Feb 2015

Two medical organizations recommend use of HPV test for cervical cancer screening

Two leading medical organizations say that using a Human papillomavirus (HPV) test alone for cervical cancer screening is an effective alternative to the current recommendation for screening with either cytology (the Pap test) alone or co-testing with cytology and HPV testing.

12 Jan 2015

New guidance recommends use of primary HPV test for cervical cancer screening

About 80 million U.S. women ages 25 to 65 should be screened periodically by their health care providers for cervical cancer. At present, the standard way to do that is a Pap smear alone, or co-testing using both a Pap smear and a human papillomavirus (HPV) test.

8 Jan 2015

Photoacoustic imaging has potential to be used as noninvasive method to detect cervical cancer

Cervical cancer is, in many ways, a shining example of how successful the war on cancer can be. Thanks largely to the advent of Pap smear screening, U.S. cervical cancer deaths decreased dramatically, by more than 60 percent, between 1955 and 1992. In the last two decades, better treatment outcomes and more powerful imaging techniques have steadily pushed 5-year survival rates ever higher.

15 Dec 2014

MD Anderson president applauds FDA's approval of new vaccine for HPV-related cancers

The Food and Drug Administration's approval of a new vaccine that targets five additional strains of human papilloma virus (HPV) fortifies a proven cancer-prevention weapon, according to Ronald A. DePinho, M.D., president of The University of Texas MD Anderson Cancer Center.

12 Dec 2014

Trovagene announces results from clinical studies on urine-based diagnostic test for detection of HPV

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that results from two clinical studies will be presented at the 29th International Papillomavirus conference for the Company's urine-based diagnostic test for the detection of high risk strains of Human Papillomavirus.

20 Aug 2014

Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Cervical cancer diagnosis is a two-step process. In developed countries, women are invited for a smear test which mainly uses LBC (liquid-based cytology), where a sample of cells are taken from the cervix and sent to a cytopathology lab for analysis.

From Zilico 19 Mar 2014

Researchers complete genomic analysis of cervical cancer in two patient populations

Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments have been approved for other forms of cancer.

25 Dec 2013

Hologic's Aptima HPV 16 18/45 genotype assay gets FDA approval for use on Panther system

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, announced today that the U.S. Food and Drug Administration has approved the Aptima HPV 16 18/45 genotype assay for use on the Company's fully automated Panther system.

From Hologic, Inc. 8 Nov 2013

Age-old practice of annual screening exams for cervical cancer may be harmful than helpful

For decades, women between the ages of 21 and 69 were advised to get annual screening exams for cervical cancer. In 2009, however, accumulating scientific evidence led major guideline groups to agree on a new recommendation that women be screened less frequently: every three years rather than annually.

10 Jul 2013

Study shows very few physicians follow HPV and cervical cancer prevention guidelines

Recent breakthroughs in cervical cancer prevention have resulted in new vaccination and cervical cancer screening guidelines. Recommendations do not always translate into practice, however.

9 Jul 2013

Early detection methods can help cure cervical cancer

Cervical cancer, a disease that will affect more than 12,000 women in the United States this year and more than a half million women worldwide, leads to significantly fewer deaths when effective early detection methods are available, either via a Pap smear or with a test for presence of the human papilloma virus.

4 Jun 2013

Sexual revolution effect may be hiding true extent of HPV prevalence

Human papillomavirus infection in older women is commonly due to reactivation of latent disease rather than new infection, research indicates.

2 Jan 2013

Guided Therapeutics files amended PMA with FDA for LuViva Advanced Cervical Scan

Guided Therapeutics, Inc., today announced that it has submitted its premarket approval (PMA) Amendment for the LuViva Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, instantly and at the point of care.

13 Nov 2012

FDA approves Hologic’s APTIMA HPV 16 18/45 Genotype Assay for use on TIGRIS system

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's APTIMA HPV 16 18/45 Genotype Assay for use on its TIGRIS instrument system.

From Hologic, Inc. 16 Oct 2012

Quest Diagnostics announces availability of TERC test for cervical cancer

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced the availability of a new laboratory test that identifies molecular changes to cervical cells that increase the likelihood a woman may develop cervical cancer.

From Quest Diagnostics 31 Aug 2012

Cervical cancer screening: an interview with Alastair Atkinson, CEO of DySIS Medical Ltd

Cervical Cancer is a tragic disease. First and foremost, because it is entirely preventable if the early symptoms are detected in a timely manner

20 Aug 2012

Cervical cancer screening product from DySIS Medical recommended by NICE

DySIS Medical Ltd, the medical devices company in female health, announces that the National Institute for Health and Clinical Excellence (‘NICE’) has today published positive diagnostics guidance recommending its DySIS cervical cancer screening product to be considered in procurement plans.

1 Aug 2012